Literature DB >> 2470678

Roles of interferon and cellular adhesion molecules in bacterial activation of human natural killer cells.

R A Lindemann1.   

Abstract

Interaction of lipopolysaccharide (LPS) from enteric and oral bacteria with natural killer (NK) cells enhanced cytotoxicity against NK-sensitive and NK-resistant targets. This activation occurred without expansion of the NK cell population or without changes in the leukocyte function-associated antigen family of cellular adhesion molecule (CAM) expression on NK cells. Significant interferon (IFN) titers were measured in LPS-lymphocyte supernatants, and antibody to IFN-alpha blocked LPS activation. LPS-induced NK cytotoxicity was inhibited by antibodies to individual alpha chains of CAM and, more profoundly, by antibody to the beta chain of CAM. However, LPS, when preincubated with NK cells, did not compete with subsequent anti-CAM antibody binding as detected by flow cytometry. Anti-CAM antibodies had no effect on NK activation by IFN, but antibodies to either CD11a or CD11c abrogated IFN production induced by LPS. These findings suggest that LPS binds NK cells at non-CAM sites, resulting in the release of IFN. IFN then acts in an autocrine manner independent of CAM to enhance NK cytotoxicity. Interaction of anti-CAM antibodies with CAM may provide a negative signal in regulating LPS-induced IFN production.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2470678      PMCID: PMC313343          DOI: 10.1128/iai.57.6.1702-1706.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Semi-micro, dye-binding assay for rabbit interferon.

Authors:  J A Armstrong
Journal:  Appl Microbiol       Date:  1971-04

2.  Functional characterization of LFA-1 antigens in the interaction of human NK clones and target cells.

Authors:  R E Schmidt; G Bartley; H Levine; S F Schlossman; J Ritz
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

3.  In vitro production of different interferon types by cloned human NK cells.

Authors:  A Nocera; G Melioli; A Merli; F Santoro; A Zicca
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

4.  Universal rosetting reagent for the detection of human cell surface markers.

Authors:  L M Karavodin; S H Golub
Journal:  J Immunol Methods       Date:  1983-07-29       Impact factor: 2.303

5.  Fetal calf serum-induced blastogenic and cytotoxic responses of human lymphocytes.

Authors:  J V Zielske; S H Golub
Journal:  Cancer Res       Date:  1976-10       Impact factor: 12.701

6.  Production of interleukin-1 and tumor necrosis factor by human peripheral monocytes activated by periodontal bacteria and extracted lipopolysaccharides.

Authors:  R A Lindemann; J S Economou; H Rothermel
Journal:  J Dent Res       Date:  1988-08       Impact factor: 6.116

7.  Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX. The quantitation of natural killer cell activity.

Authors:  H F Pross; M G Baines; P Rubin; P Shragge; M S Patterson
Journal:  J Clin Immunol       Date:  1981-01       Impact factor: 8.317

8.  Natural killer cell activation and interferon production by peripheral blood lymphocytes after exposure to bacteria.

Authors:  G R Klimpel; D W Niesel; M Asuncion; K D Klimpel
Journal:  Infect Immun       Date:  1988-06       Impact factor: 3.441

9.  Impaired production of gamma-interferon by newborn cells in vitro is due to a functionally immature macrophage.

Authors:  S Taylor; Y J Bryson
Journal:  J Immunol       Date:  1985-03       Impact factor: 5.422

10.  Characteristics of human large granular lymphocytes and relationship to natural killer and K cells.

Authors:  T Timonen; J R Ortaldo; R B Herberman
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

View more
  8 in total

1.  Potentiation of human natural killer cell cytotoxicity by Salmonella bacteria is an interferon- and interleukin-2-independent process that utilizes CD2 and CD18 structures in the effector phase.

Authors:  J Tarkkanen; E Saksela
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

2.  Mycobacterial induction of activated killer cells: possible role of tyrosine kinase activity in interleukin-2 receptor alpha expression.

Authors:  D K Blanchard; S McMillen; S L Hoffman; J Y Djeu
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

3.  The effects of staphylococcal protein A on human lymphokine-activated killer cell induction.

Authors:  R A Lindemann; K P Singh; H Shau; R K Gupta
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

4.  Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: role of prostaglandin E2 and interferons.

Authors:  D Vaillier; R Daculsi; N Gualde
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

5.  Listeria monocytogenes activation of human peripheral blood lymphocytes: induction of non-major histocompatibility complex-restricted cytotoxic activity and cytokine production.

Authors:  Y Guo; D W Niesel; H K Ziegler; G R Klimpel
Journal:  Infect Immun       Date:  1992-05       Impact factor: 3.441

6.  Functional characterization of human natural killer cells responding to Mycobacterium bovis bacille Calmette-Guérin.

Authors:  Semih Esin; Giovanna Batoni; Manuela Pardini; Flavia Favilli; Daria Bottai; Giuseppantonio Maisetta; Walter Florio; Renato Vanacore; Hans Wigzell; Mario Campa
Journal:  Immunology       Date:  2004-05       Impact factor: 7.397

7.  Rapid generation of specific protective immunity to Francisella tularensis.

Authors:  K L Elkins; D A Leiby; R K Winegar; C A Nacy; A H Fortier
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

8.  TLR engagement induces ARID3a in human blood hematopoietic progenitors and modulates IFNα production.

Authors:  Michelle L Ratliff; Malini Shankar; Joel M Guthridge; Judith A James; Carol F Webb
Journal:  Cell Immunol       Date:  2020-09-09       Impact factor: 4.868

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.